The Human Microbiome and Its Role in Musculoskeletal Disorders
Authors:
- Khaled AboushaalaKAKhaled Aboushaala
- Arnold Y. L. WongArnold Y. L. Wong
- Juan Nicolas BarajasJBJuan Nicolas Barajas
- Perry LimPLPerry Lim
- Lena Al-HarthiLALena Al-Harthi
- Ana CheeACAna Chee
- Christopher B. ForsythCFChristopher B. Forsyth
- Chun-Do OhChun-Do Oh
- Sheila J. ToroSTSheila J. Toro
- Frances M. K. WilliamsFWFrances M. K. Williams
- Howard S. AnHAHoward S. An
- Dino SamartzisDSDino Samartzis
Open Access
Abstract
Musculoskeletal diseases (MSDs) are characterized as injuries and illnesses that affect the musculoskeletal system. MSDs affect every population worldwide and are associated with substantial global burden. Variations in the makeup of the gut microbiota may be related to chronic MSDs. There is growing interest in exploring potential connections between chronic MSDs and variations in the composition of gut microbiota. The human microbiota is a complex community consisting of viruses, archaea, bacteria, and eukaryotes, both inside and outside of the human body. These microorganisms play crucial roles in influencing human physiology, impacting metabolic and immunological systems in health and disease. Different body areas host specific types of microorganisms, with facultative anaerobes dominating the gastrointestinal tract (able to thrive with or without oxygen), while strict aerobes prevail in the nasal cavity, respiratory tract, and skin surfaces (requiring oxygen for development). Together with the immune system, these bacteria have coevolved throughout time, forming complex biological relationships. Changes in the microbial ecology of the gut may have a big impact on health and can help illnesses develop. These changes are frequently impacted by lifestyle choices and underlying medical disorders. The potential for safety, expenses, and efficacy of microbiota-based medicines, even with occasional delivery, has attracted interest. They are, therefore, a desirable candidate for treating MSDs that are chronic and that may have variable progression patterns. As such, the following is a narrative review to address the role of the human microbiome as it relates to MSDs.Keywords
Funding Information
- National Institutes of Health (R21AR079679)
- Thomas J. Coogan, Chair of Immunology Endowment (LA) (R21AR079679)
This publication has 231 references indexed in Scilit:
- Host Remodeling of the Gut Microbiome and Metabolic Changes during PregnancyCell, 2012
- Human gut microbiome viewed across age and geographyNature, 2012
- The gut microbiota regulates bone mass in miceJournal of Bone and Mineral Research, 2012
- Gut flora metabolism of phosphatidylcholine promotes cardiovascular diseaseNature, 2011
- Ageing of the human metaorganism: the microbial counterpartAGE, 2011
- Viruses in the faecal microbiota of monozygotic twins and their mothersNature, 2010
- Induction of Intestinal Th17 Cells by Segmented Filamentous BacteriaCell, 2009
- The Human Microbiome ProjectNature, 2007
- Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and postmenopausal women: evidence for a link between systemic inflammation and osteoporosisOsteoporosis International, 2005
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002